Reglan and Tardive Dyskinesia: Understanding the Risk Factors and Monitoring Needs

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Awareness to Specific Risk: The Legacy of Medication Safety

If you or a loved one has been taking Reglan (metoclopramide) and notice involuntary movements like lip smacking or tongue thrusting, you may be experiencing tardive dyskinesia. Decades of pharmacovigilance have established that prolonged use of this medication carries a well-documented risk of this neurological condition. This page explains who is most at risk and what monitoring can help detect early signs.

Reglan and Tardive Dyskinesia: A Bridge to Legal Considerations

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis, but its association with tardive dyskinesia (TD) has led to significant litigation in Ohio and elsewhere. The statute of limitations for filing a Reglan TD claim in Ohio is generally governed by the state's personal injury laws, which typically require a lawsuit to be filed within two years from the date the injury was discovered or reasonably should have been discovered. For TD, this timeline can be complex because symptoms may develop gradually after exposure to Reglan. Tardive dyskinesia is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after the offending medication is discontinued. Reglan's prescribing information includes a boxed warning stating that metoclopramide can cause TD, and the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also notes that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Injury and Risk Factors

Mechanistically, metoclopramide acts as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to upregulation of these receptors and subsequent supersensitivity, which manifests as the involuntary movements characteristic of TD. The label warns that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can complicate the recognition of early symptoms and may affect the statute of limitations clock, as the injury might not be discovered until after the drug is discontinued. The approved indications for Reglan are limited to 4 to 12 weeks for gastroesophageal reflux and for relief of symptoms in diabetic gastroparesis, with a maximum duration of 12 weeks for both conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these restrictions, many patients were prescribed Reglan for extended periods, sometimes years, which increased their risk of developing TD. The label explicitly states that Reglan has not been shown to be safe and effective for gastroesophageal reflux beyond 12 weeks and that pediatric use is not recommended due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations and Settlement Considerations in Ohio

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue in litigation. The boxed warning is prominent, but plaintiffs often argue that prescribers and patients were not adequately informed about the risk of TD with long-term use, especially for off-label indications or durations exceeding 12 weeks. The label advises that in patients with diabetic gastroparesis, if longer-term use is unavoidable, routine monitoring for TD signs and symptoms should be performed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were not monitored, and TD was diagnosed only after significant progression. Settlement considerations for affected patients in Ohio depend on several factors, including the severity of TD, the duration of Reglan use, the presence of documented warnings, and the timing of diagnosis relative to exposure. The statute of limitations is a critical threshold; if a patient discovered or should have discovered their TD more than two years before filing a claim, the case may be time-barred. Ohio courts apply the discovery rule, meaning the clock starts when the plaintiff knew or reasonably should have known that Reglan caused their injury. For TD, this often coincides with a formal diagnosis by a neurologist or movement disorder specialist. The timeline between exposure and documented harm is variable. Some patients develop TD within months of starting Reglan, while others may not show symptoms until after years of use. The label states that risk increases with duration and cumulative dose, but there is no safe duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD is diagnosed, the condition is often irreversible, and treatment focuses on symptom management. The label instructs immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Ohio patients who developed TD after Reglan use should be aware of the two-year statute of limitations from the date of discovery. The adequacy of warnings, the duration of exposure, and the timing of diagnosis are key factors in settlement negotiations. Legal counsel experienced in pharmaceutical litigation can help assess individual circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Ohio?

In Ohio, the statute of limitations for personal injury claims, including those for Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. This is known as the discovery rule. For tardive dyskinesia, the clock typically starts when a patient receives a formal diagnosis from a neurologist or movement disorder specialist.

Can I still file a claim if my tardive dyskinesia symptoms appeared years after stopping Reglan?

Yes, you may still be able to file a claim if the symptoms were not discovered until later. The statute of limitations begins when you knew or should have known that Reglan caused your injury. However, it is important to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.